Navigation Links
Cellectis bioresearch Makes Genome Engineering Affordable for All Users
Date:2/28/2011

PARIS, Feb. 28, 2011 /PRNewswire/ -- Cellectis bioresearch, a specialist in genome customization and subsidiary of Cellectis (Alternext: ALCLS), has today launched TALEN Access™, the first fee-for-service custom TALEN(1).

Recognized as a pioneer in the development of innovative research products for genome customization, Cellectis bioresearch brings today the life sciences community a new tool for specifically modifying genes in any type of cell.

The service will start with the TALEN Access™ offer, which provides a pair of TALENs for 5,000 euro/US$, delivered in less than 3 weeks.

"What we are offering here is a true commercial revolution," said Luc Selig, VP Sales and Marketing at Cellectis bioresearch. "We are keeping our promise to make genome customization affordable for the hundred of thousands academic research labs."

For further information or to place orders, please go to www.cellectis-bioresearch.com/talen.

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on sequence specific nucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies.

The kits can be purchased online from www.cellectis-bioresearch.com. More information on the website.

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

More information at www.cellectis.com.

Follow Cellectis on Twitter at www.twitter.com/cellectis.  

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with the IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

(1) TALEN: Transcription Activator-Like Effector Nuclease


'/>"/>
SOURCE Cellectis bioresearch
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellectis In-Licenses Induced Pluripotent Stem Cell Technology From iPS Academia Japan
2. Cellectis Publishes Its Financial Statement for the First Half of 2010
3. Cellectis bioresearch Announces Establishment of Subsidiary in the US
4. Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India
5. Cellectis Bioresearch and Cedarlane Join Forces for the Distribution of cGPS® and cGPS® Custom Kits in Canada
6. New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearchs cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery
7. SAP Makes Life Easier for Patients and More Efficient for Healthcare Providers Through New Technology
8. Pinnaclife Makes it Official With Launch Slated for March 1st
9. Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
10. US FDA Advisory Committee Makes Recommendation on New Drug Application for Vandetanib in Advanced Medullary Thyroid Cancer
11. Panasonic Makes Investment in Houston-based CardioNexus Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... will be participating in the Deutsche Bank Securities 42nd ... Boston, Massachusetts on Wednesday, May ... Eastern Time. A live webcast of the ... website at http://investor.zimmerbiomet.com .  The webcast will be ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... R.I. , April 20, 2017  CVS ... CVS), today unveiled a new store design to ... assortment of healthier food, health-focused products and expanded ... store to help customers discover new offerings. Together ... the next evolution of the customer experience at ...
Breaking Medicine Technology:
(Date:4/28/2017)... LINCOLN, R.I. (PRWEB) , ... April 28, 2017 , ... Getting enough sleep affects much ... Sleep Foundation (NSF), going just 19 hours without sleep can compromise motor reaction time, which ... Awareness Week, and Amica Insurance is sharing the following tips from the NSF to help ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management ... officers for 2017-2018. The annual board election process has been in place since the ... , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. ...
(Date:4/28/2017)... ... April 28, 2017 , ... From April ... of Urgent Care Medicine will host industry leaders for the annual spring Convention ... those in the industry adapt to the issues currently affecting urgent care and ...
(Date:4/28/2017)... ... ... and Overseer at The House of Yahweh in Abilene, Texas, has published a new post ... Yisrayl says with so many titles and names for the Creator, it’s hard for ... little Scripture, backed with a lot of research, the truth is undeniable. , “If ...
(Date:4/28/2017)... New York, New York (PRWEB) , ... April ... ... of high-quality anti-aging skincare and advanced nutraceutical supplements, through its Nova ... fast-absorbing cream provides the hydrating benefits of a moisturizer with the power of ...
Breaking Medicine News(10 mins):